DS Biopharma appoints Leopoldo Zambeletti as Non-Executive Director

Dublin, Ireland, September 25, 2015 – DS Biopharma, a privately held biopharmaceutical company, today announced the appointment of Leopoldo Zambeletti as a Non-Executive Director to the Company’s Board.

Mr. Zambeletti is a highly respected figure within the life sciences sector. During a 19 year career as an investment banker, he led the European Healthcare Investment team at JP Morgan for eight years before taking up the same position at Credit Suisse for a further five years. Since 2013 Mr Zambeletti has been an independent strategic advisor to life science companies on Merger and Acquisitions, out-licensing deals and financing strategy. He is a Non-Executive Director of Nogra Pharma, Advanced Accelerator Applications, Faron Pharmaceuticals, Summit Therapeutics plc. and an advisor and co-founder to the US medtech company Qardio. He serves as a trustee to Barts and the London Charity, which helps to fund the hospitals of the Barts NHS Trust including St. Bartholomew, the Royal London and the London Chest Hospitals, and he is a founder of the cultural initiative 5×15 Italy. Mr Zambeletti started his career at KPMG as an accountant.

“I am delighted to welcome Leopoldo to DS Biopharma’s Board of Directors,” commented Dr. John Climax, Executive Chairman of DS Biopharma. “He has built up extensive experience in his previous senior positions in the life sciences sector and will complement the skill sets of the other DS Biopharma Board members. We look forward to Leopoldo’s contribution to the strategy of DS Biopharma as we progress our pipeline of bioactive lipids through clinical development.”

About DS Biopharma

DS Biopharma, headquartered in Dublin, Ireland, is a privately held drug discovery and development company working on new medicines that improve the quality of life for people with diseases for which existing therapies are ineffective. DS has developed a proprietary library of bioactive lipids from which it is working on new approaches to treat inflammatory skin disorders.

For more information, visit https://www.dsbiopharma.com



DS Biopharma: investorrelations@dsbiopharma.com, +35312933590